Lv1
51 积分 2020-10-23 加入
The evolving landscape of obesity pharmacotherapy
29天前
已完结
New immune cell engagers for cancer immunotherapy
2个月前
已完结
Immune-mediated inflammatory disease therapeutics: past, present and future
2个月前
已完结
Can multispecific biologics break the efficacy ceiling?
2个月前
已完结
Multispecific T-cell engagers attract cancer drug developers
2个月前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
2个月前
已完结
Landscape of tumor-infiltrating T cell repertoire of human cancers
2个月前
已完结
Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer
2个月前
已完结
The immune microenvironment of colorectal cancer
2个月前
已完结
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
3个月前
已完结
皖公网安备34019202002308
